Chronic Obstructive Pulmonary Disease Market Size was valued at USD 16,075 million in 2023, estimated DelveInsight

DelveInsight’s “Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Obstructive Pulmonary Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. 

The Chronic Obstructive Pulmonary Disease Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Obstructive Pulmonary Disease prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Obstructive Pulmonary Disease market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities. 

Discover Key Insights into the Chronic Obstructive Pulmonary Disease Market with DelveInsight’s In-Depth Report @ Chronic Obstructive Pulmonary Disease Market Size 

Key Takeaways from the Chronic Obstructive Pulmonary Disease Market Report

• In November 2024;- Merck Sharp & Dohme LLC- A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take MK-5475 can walk farther in 6 minutes at Week 24 compared to people who take placebo.
• In November 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease. This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
• In November 2024:- Sanofi- The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819.
• In November 2024:- AstraZeneca- A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE).
• DelveInsight’s analyst estimate that approximately 44.2 million Diagnosed Prevalent Cases of COPD were found in 2023 in the 7MM.
• The United States exhibited the highest diagnosed prevalent population of COPD, as compared to other 7MM countries. As per DelveInsight’s estimations, the Total Diagnosed Prevalent Cases of COPD in the US was around 18.3 million in 2023 and is projected to increase during the forecast period owing to the increasing prevalence of smoking, improved diagnosis and increasing awareness among the patient population.
• According to DelveInsight’s estimates, the Total Diagnosed Prevalent Cases of COPD in EU4 and the UK were found to be ~18.6 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of COPD cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.
• The estimates show the Total Diagnosed Prevalent Cases of COPD in Japan was found to be around 7.2 million in 2023, which is estimated to increase by 2034 at a significant CAGR.
• The Gender-specific Cases of COPD in the UK were ~1.7 million for females and ~2 million for males in 2023 and are expected to increase within the forecast period (2024–2034). The increased prevalence in females is likely due to a combination of factors, including genetics, environmental factors, and healthcare inequalities, among others.
• According to the analysis performed by DelveInsight’s experts, the Age-specific Cases of COPD were categorized into 18-44 years, 45-54 years, 55-64 years, 65-74 years, and 75+ years. The higher number of cases (~4.8 million) was accounted for by the 55-64 year age group in 2023 in the US.
• The leading Chronic Obstructive Pulmonary Disease Companies such as Sanofi/Regeneron Pharmaceuticals, Verona Pharma PLC, Regeneron Pharmaceuticals, AstraZeneca, GlaxoSmithKline (), Mereo BioPharma, and others.
• Promising Chronic Obstructive Pulmonary Disease Therapies such as Itepekimab, Ensifentrine, Dupilumab, Acumapimod, Benralizumab, Mepolizumab, and others.

Stay ahead in the Chronic Obstructive Pulmonary Disease Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Obstructive Pulmonary Disease Market Outlook

Chronic Obstructive Pulmonary Disease Epidemiology

• Total Diagnosed Prevalent Cases
• Subtype-specific Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation,
• Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History

Download the report to understand which factors are driving Chronic Obstructive Pulmonary Disease epidemiology trends @ Chronic Obstructive Pulmonary Disease Prevalence

Chronic Obstructive Pulmonary Disease Marketed Drugs

• Duaklir Pressair (aclidinium/formoterol fumarate): AstraZeneca

Approved in April 2019, Duaklir (aclidinium bromide/formoterol fumarate 400 µg/12 µg twice-daily) is a fixed-dose LAMA/LABA combination of two long-acting bronchodilators – aclidinium bromide is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta-agonist (LABA). Duaklir Pressair contains two bronchodilators: aclidinium, a long-acting muscarinic antagonist (also known as an anticholinergic), and formoterol, a long-acting beta-2-adrenergic agonist.

• DUPIXENT (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Dupixent (dupilumab) is a monoclonal antibody targeting the alpha chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response. Dupilumab is approved in the US to treat patients aged =12 with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. The drug is currently in Phase III of clinical development for COPD.

In September 2024, the US FDA approved DUPIXENT (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype.

Chronic Obstructive Pulmonary Disease Emerging Drugs

• Itepekimab (SAR440340/REGN3500): Sanofi/Regeneron Pharmaceuticals

REGN3500 is a fully human monoclonal antibody that inhibits interleukin-33 (IL-33), a protein that is believed to play a key role in type 1 and type 2 inflammation. The drug is administered subcutaneously. Preclinical research showed REGN3500 blocked several markers of both types of inflammation. Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation plays an underlying role. REGN3500 is being studied in Phase III trial for COPD.

In January 2023, itepekimab received FTD from the US FDA for the treatment of COPD.

• FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab), currently in Phase III, is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. Besides, it is an afucosylated IgG which gives it a high affinity for the Fc?RIIIa receptor in natural killer cells, macrophages, and neutrophils.

Get In-Depth Knowledge on Chronic Obstructive Pulmonary Disease Market Trends and Forecasts with DelveInsight @ Chronic Obstructive Pulmonary Disease Treatment Market

Chronic Obstructive Pulmonary Disease Market Outlook

Chronic Obstructive Pulmonary Disease is a common, preventable, and treatable chronic lung disease that affects men and women worldwide. Abnormalities in the lungs’ small airways lead to limitation of airflow in and out of the lungs. Several processes cause the airways to become narrow. There may be the destruction of parts of the lung, mucus blocking the airways, inflammation, and swelling of the airway lining. COPD and asthma share common symptoms (coughing, wheezing, and difficulty breathing), and people may have both conditions.

Scope of the Chronic Obstructive Pulmonary Disease Market Report 

• Coverage- 7MM
• Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others
• Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others
• Chronic Obstructive Pulmonary Disease Market Dynamics: Attribute Analysis of Emerging Chronic Obstructive Pulmonary Disease Drugs
• Chronic Obstructive Pulmonary Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Chronic Obstructive Pulmonary Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Obstructive Pulmonary Disease Market Report @ Chronic Obstructive Pulmonary Disease Market Drivers and Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Obstructive Pulmonary Disease (COPD) Market Overview at a Glance

4. Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)

5. Key Events

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Organizations contributing towards Chronic Obstructive Pulmonary Disease (COPD)

10. Marketed Therapies

11. Emerging Drugs

12. Chronic Obstructive Pulmonary Disease (COPD): Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/